A Study to Assess New Formulations of TEV-56286

Study Title
An Open-Label, Randomized, Crossover Study to Assess the Comparative Bioavailability of New TEV-56286 Formulations Compared to a Reference TEV-56286 Capsule Formulation Following Single-Dose Administration in Healthy Participants
Teva Identifier
TV56286-BA-10218
ClinicalTrials.gov Identifier
NCT06911567
Study Status
Recruiting
Trial Condition(s)
Healthy Participants
Interventions
Drug: TEV-56286 Test | Drug: TEV-56286 Reference

Study Description

The primary objective of the study is to assess the relative bioavailability of TEV-56286 test formulations compared to TEV-56286 reference product in healthy adult participants.

The secondary objective is to evaluate the safety and tolerability of TEV-56286.

The planned duration for each participant is approximately 70 days which includes a 45 day screening period.

Print

Participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age group
Adult
Age Range
18 years to 60 Years
Trial Duration
March 10, 2025 - May 29, 2025
Phase
Phase 1

Study Type

Interventional